Effects of clodronate and pamidronate on splenic and hepatic phagocytic cells of mice.

Pharmacol Toxicol

Department of Pharmacology and Toxicology, University of Kuopio, Finland.

Published: April 1991

Bisphosphonates inhibit the activity of osteoclasts and conceivably also macrophage activity. Administered in hypoosmotic solution, clodronate (dichloromethylene bisphosphonate) forms complexes with the iron of haemolysed erythrocytes and subsequently accumulates in splenic and hepatic macrophages. Pamidronate (3-amino-1-hydroxypropylidene bisphosphonate) also accumulates in the spleen and liver of mice and rats even when injected in isoosmotic solution. In the present study, the effects in mice of uncomplexed clodronate, clodronate-iron complex, clodronate-liposomes, and pamidronate on splenic and hepatic macrophages in vivo were studied by an enzyme-histochemical method. Intracellular free clodronate released in the cells after phagocytosis of clodronate-liposomes virtually eliminated all macrophages from spleen, and also Kuppfer cells from liver. Clodronate given in hypoosmotic vehicle had no effect on these cells, although it was taken up by them. Clodronate in isoosmotic vehicle, considered as uncomplexed clodronate, neither accumulates in nor affects the macrophages. Pamidronate, however, decreased the number of the cells also after isoosmotic injection. Thus, the capability of bisphosphonates to sequestrate intracellular calcium may explain their effects on macrophages.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0773.1991.tb01240.xDOI Listing

Publication Analysis

Top Keywords

splenic hepatic
12
pamidronate splenic
8
hepatic macrophages
8
macrophages pamidronate
8
uncomplexed clodronate
8
clodronate
6
cells
5
macrophages
5
effects clodronate
4
pamidronate
4

Similar Publications

Goals: To explore dynamic contrast-enhanced ultrasound (CEUS) parameters in predicting hepatic vein pressure gradient (HVPG) for patients with liver cirrhosis (LC).

Background: Noninvasive diagnosis of HVPG remains a challenge.

Study: This prospective study included patients with LC undergoing hepatic vein catheterization and pressure measurement at the hospital from May 2021 to January 2023.

View Article and Find Full Text PDF

Prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma through ultrasound elastography.

World J Gastroenterol

January 2025

Department of Radiology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China.

In this article, we comment on the article by Cheng published in recently. Posthepatectomy liver failure (PHLF) remains a leading cause of hepatectomy-related mortality and can be evaluated according to liver reserve function. Liver stiffness (LS) measured by ultrasonic elastography and spleen area demonstrate a strong correlation with hepatic proliferation, fibrosis, and portal vein congestion, thus indirectly reflecting liver reserve function.

View Article and Find Full Text PDF

Purpose: We present the case of a rare extrahepatic portocaval shunt that resulted in communication of the portal vein and the inferior vena cava (IVC) at the level between two right renal veins that was incidentally diagnosed with contrast-enhanced computed tomography (CECT) in an asymptomatic patient.

Methods: A woman in her sixties with abdominal pain and diarrhea of unclear origin underwent exploratory abdominal CECT.

Results: The CECT incidentally revealed an extrahepatic portocaval shunt, whereby a vessel arising from the portal vein superior to the confluence of the superior mesenteric and splenic veins drained into the posterior aspect of the IVC between two right renal veins.

View Article and Find Full Text PDF

Fostamatinib had superior efficacy to a placebo and acceptable safety profiles for at least 1 year in a phase 3 study of Japanese patients with primary immune thrombocytopenia. Here, we report the 3-year safety and efficacy of fostamatinib in that study. Data from 33 patients who received at least one dose of fostamatinib were analyzed.

View Article and Find Full Text PDF

Background: T/histiocyte-rich large B-cell lymphoma (T/HRBCL) is a highly aggressive subtype of diffuse large B-cell lymphoma characterized histologically by the presence of a few neoplastic large B cells amidst an abundant background of reactive T lymphocytes and/or histiocytes. T/HRBCL commonly affects the lymph nodes, followed by extranodal sites, such as the spleen, liver, and bone marrow, with rare occurrences in the gastrointestinal tract. Primary gastrointestinal T/HRBCL lacks specific clinical and endoscopic manifestations, and it is difficult to differentiate from inflammatory diseases, nodular lymphocyte predominant Hodgkin lymphoma, and other diseases on a histological basis, thereby hindering early diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!